Note: Javascript is disabled or is not supported by your browser. For this reason, some items on this page will be unavailable. For more information about this message, please visit this page: About CDC.gov.

Risk for Transfusion-Transmitted Infectious Diseases in Central and South America

Table 2

Probability of receiving an infected transfusion P(R)a and probability of getting a transfusion-transmitted infection P(I)b, by countryc

HIV (x104)

HBV (x104)

HCV (x104)

T. cruzi (x104)

Country

P(R)

P(I)

P(R)

P(I)

P(R)

P(I)

P(R)

P(I)

Bolivia

0.64

0.57

17.27

12.95

NSPd

NSP

1096.38

219.28

Chile

0.00

0.00

0.26

0.20

46.46

41.82

29.36

5.87

Colombia

0.24

0.22

1.20

0.90

74.55

67.09

124.24

24.85

Costa Rica

0.00

0.00

0.45x

0.34

NSP

NSP

NSP

NSP

Ecuador

1.05

0.95

4.52

3.39

10.33

9.38

10.29

2.06

El Salvador

0.00

0.00

3.23

2.42

18.87

16.97

88.75

17.75

Guatemala

0.00

0.00

14.28

10.71

55.26

49.74

36.75

7.35

Honduras

0.00

0.00

4.49

3.37

3.97

3.57

13.02x

2.60

Nicaragua

0.00

0.00

18.95

14.21

22.70

20.43

10.48

2.10

Paraguay

0.00

0.00

9.32

6.99

NSP

NSP

62.37

12.47

Peru

0.00

0.00

0.87x

0.65

20.62

18.56

247.80

49.56

Venezuela

0.00

0.00

1.45x

1.09

71.35

64.21

13.86 x

2.77

aP(R) = probability of receiving an infected transfusion = prevalence of infection x 1- level of screening; xfor countries in which reported screening level was 100%, a residual P(R) was estimated as prevalence x 1- screening sensitivity rate x 10,000.bP(I) = probability of getting a transfusion-transmitted infection = P(R) x infectivity index (infectivity indexes used were HIV=90%; HBV=75%; HCV=90%; T.cruzi=20%). For calculations of P(R) and P(I) the prevalence was corrected taking into account the sensitivity of the screening.cData from 1993, except for Ecuador and Paraguay, which were for 1994.dNo screening performed, so P(R) and P(I) not known.

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.